Adaptive Biotechnologies Reports Strong Q4 & FY2025 Results, Achieves MRD Profitability, Guides for 2026 Growth

summarizeSummary

Adaptive Biotechnologies reported robust financial results for Q4 and full year 2025, marked by significant revenue growth, reduced net losses, and the achievement of positive Adjusted EBITDA, particularly within its Minimal Residual Disease (MRD) business, alongside optimistic 2026 guidance.

check_boxKey Events

• Strong Q4 and FY2025 Revenue Growth

  Reported Q4 2025 revenue of $71.7 million, a 51% increase year-over-year, and full year 2025 revenue of $277.0 million, a 55% increase year-over-year.

• Achieved Positive Adjusted EBITDA

  The company achieved positive Adjusted EBITDA of $4.1 million in Q4 2025 and $12.2 million for the full year 2025, a significant improvement from prior year losses.

• MRD Business Achieves Profitability

  The Minimal Residual Disease (MRD) business achieved positive Adjusted EBITDA and positive cash flow, with revenue growing 54% in Q4 and 46% for the full year.

• Positive 2026 Guidance

  Provided 2026 full year revenue guidance for the MRD business between $255 million and $265 million, indicating continued growth, and expects to achieve company-wide profitability.

auto_awesomeAnalysis

Adaptive Biotechnologies delivered a strong performance in Q4 and full year 2025, significantly exceeding prior year results. The company achieved substantial revenue growth of 51% in Q4 and 55% for the full year, driven by its core Minimal Residual Disease (MRD) business. A key highlight is the MRD segment achieving positive Adjusted EBITDA and cash flow, signaling a critical step towards overall profitability. The company also significantly reduced its net loss and achieved positive Adjusted EBITDA at the total company level for both the fourth quarter and the full year. Strategic advancements, including expanded Medicare coverage for clonoSEQ and new data licensing agreements with Pfizer, further bolster its market position. The positive 2026 revenue guidance for the MRD business, coupled with a focus on disciplined capital allocation, positions Adaptive Biotechnologies for continued growth and company-wide profitability.